Adam Rosenthal, Vega Therapeutics CEO

A new Ve­ga en­ters the galaxy with bleed­ing dis­or­der an­ti­body set for 2023 tri­al

Biotech in­cu­ba­tor Star Ther­a­peu­tics has launched an­oth­er galaxy-themed drug de­vel­op­er, which next year will test a new an­ti­body in a bleed­ing dis­or­der cur­rent­ly treat­ed by Take­da’s Von­ven­di.

Star lined up a who’s who of biotech ven­ture cap­i­tal firms to line Ve­ga Ther­a­peu­tics’ cof­fers with $40 mil­lion. The funds will bankroll a Phase I study ear­ly next year as the biotech re­cent­ly got the go-ahead from Aus­tri­an au­thor­i­ties, CEO Adam Rosen­thal told End­points News in a pre­view of the un­veil­ing. The biotech will test whether a mon­o­clon­al an­ti­body can treat one of the most com­mon forms of in­her­it­ed bleed­ing dis­or­ders: von Wille­brand dis­ease, or VWD.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.